203 related articles for article (PubMed ID: 33087068)
1. Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx).
Phinyo P; Maihom T; Phanphaisarn A; Kerdsinchai P; Rattarittamrong E; Patumanond J; Pruksakorn D
BMC Fam Pract; 2020 Oct; 21(1):215. PubMed ID: 33087068
[TBL] [Abstract][Full Text] [Related]
2. Validation of a Diagnostic Model to Differentiate Multiple Myeloma from Bone Metastasis.
Phinyo P; Jarupanich N; Lumkul L; Phanphaisarn A; Poosiripinyo T; Sukpanichyingyong S; Thanindratarn P; Pornmeechai Y; Wisanuyotin T; Phimolsarnti R; Rattarittamrong E; Pruksakorn D
Clin Epidemiol; 2023; 15():881-890. PubMed ID: 37522153
[TBL] [Abstract][Full Text] [Related]
3. Correction: Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx).
Phinyo P; Maihom T; Phanphaisarn A; Kerdsinchai P; Rattarittamrong E; Patumanond J; Pruksakorn D
BMC Prim Care; 2022 Jul; 23(1):189. PubMed ID: 35902790
[No Abstract] [Full Text] [Related]
4. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of artificial intelligence-supported assessment of bone marrow infiltration using dual-energy computed tomography in patients with evidence of monoclonal protein - a retrospective observational study.
Fervers P; Fervers F; Kottlors J; Lohneis P; Pollman-Schweckhorst P; Zaytoun H; Rinneburger M; Maintz D; Große Hokamp N
Eur Radiol; 2022 May; 32(5):2901-2911. PubMed ID: 34921619
[TBL] [Abstract][Full Text] [Related]
7. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
[TBL] [Abstract][Full Text] [Related]
8. Application of an artificial intelligence-based tool in [
Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665
[TBL] [Abstract][Full Text] [Related]
9. Differential Performances in Lesions and Radiotracer of
Deng C; Han D; Zhang X; Lv Z; Li D
Curr Med Imaging; 2023; 19(7):713-719. PubMed ID: 35578864
[TBL] [Abstract][Full Text] [Related]
10. Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.
Dankerl A; Liebisch P; Glatting G; Friesen C; Blumstein NM; Kocot D; Wendl C; Bunjes D; Reske SN
Radiology; 2007 Feb; 242(2):498-508. PubMed ID: 17179397
[TBL] [Abstract][Full Text] [Related]
11. Metabolic markers for diagnosis and risk-prediction of multiple myeloma.
Fei F; Ma T; Zhou X; Zheng M; Cao B; Li J
Life Sci; 2021 Jan; 265():118852. PubMed ID: 33278388
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].
Zhao JT; Jiang XY; Yang C; Chen M; Lan XL; Du JH; Zhou DB; Zhuang JL
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):295-301. PubMed ID: 33979973
[No Abstract] [Full Text] [Related]
13. Can a Novel Scoring System Improve on the Mirels Score in Predicting the Fracture Risk in Patients with Multiple Myeloma?
Toci GR; Bressner JA; Morris CD; Fayad L; Levin AS
Clin Orthop Relat Res; 2021 Mar; 479(3):521-530. PubMed ID: 32420721
[TBL] [Abstract][Full Text] [Related]
14. A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease.
Hofgaard PO; Jodal HC; Bommert K; Huard B; Caers J; Carlsen H; Schwarzer R; Schünemann N; Jundt F; Lindeberg MM; Bogen B
PLoS One; 2012; 7(12):e51892. PubMed ID: 23284805
[TBL] [Abstract][Full Text] [Related]
15. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic role of annexin A2 in multiple myeloma.
Seckinger A; Meissner T; Moreaux J; Depeweg D; Hillengass J; Hose K; Rème T; Rösen-Wolff A; Jauch A; Schnettler R; Ewerbeck V; Goldschmidt H; Klein B; Hose D
Blood; 2012 Aug; 120(5):1087-94. PubMed ID: 22705595
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of machine learning-based computed tomography texture analysis for differentiating multiple myeloma from osteolytic metastatic bone lesions in the peripheral skeleton.
Özgül HA; Akin IB; Mutlu U; Balci A
Skeletal Radiol; 2023 Sep; 52(9):1703-1711. PubMed ID: 37014470
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the bone turnover markers in multiple myeloma.
Auzina D; Erts R; Lejniece S
Exp Oncol; 2017 Mar; 39(1):53-56. PubMed ID: 28361850
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.
Riedel SS; Mottok A; Brede C; Bäuerlein CA; Jordán Garrote AL; Ritz M; Mattenheimer K; Rosenwald A; Einsele H; Bogen B; Beilhack A
PLoS One; 2012; 7(12):e52398. PubMed ID: 23300660
[TBL] [Abstract][Full Text] [Related]
20. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis.
Hao M; Zang M; Zhao L; Deng S; Xu Y; Qi F; An G; Qin Y; Sui W; Li F; Yang W; Li Z; Yi S; Zou D; Zhan F; Qiu L
Oncotarget; 2016 Apr; 7(15):19589-600. PubMed ID: 26995755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
